HMGB1 is increased by CFTR loss of function, is lowered by insulin, and increases in vivo at onset of CFRD

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 3, 2016, Pages 1274-1281

  Montanini, Luisa ^a   Cirillo, Francesca ^b   Smerieri, Arianna ^a,b   Pisi, Giovanna ^a   Giardino, Ida ^c   D'Apolito, Maria ^c   Spaggiari, Cinzia ^a   Bernasconi, Sergio ^a   Amarri, Sergio ^a   Street, Maria Elisabeth ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HIGH MOBILITY GROUP B1 PROTEIN; INSULIN; BIOLOGICAL MARKER; CFTR PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL; HMGB1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ADULT; ARTICLE; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS RELATED DIABETES; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE SILENCING; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; IN VIVO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; CELL CULTURE; CHILD; COMPLICATION; CYSTIC FIBROSIS; DIABETES MELLITUS; GENETICS; METABOLISM; PHYSIOLOGY; RNA INTERFERENCE; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CELLS, CULTURED; CHILD; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIABETES MELLITUS; FEMALE; HMGB1 PROTEIN; HUMANS; INSULIN; MALE; RNA INTERFERENCE; RNA, SMALL INTERFERING; YOUNG ADULT;

EID: 84960906011     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3730     Document Type: Article

References (41)

1. Costa M, Potvin S, Berthiaume Y, et al. Diabetes: a major co-morbidity of cystic fibrosis. Diabetes Metab. 2005;31(3 pt 1):221-232.
2. Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of cystic fibrosis-related diabetes. J Cyst Fibrosis. 2004;3(4):209-222.
3. Hardin DS, Leblanc A, Marshall G, Seilheimer DK. Mechanisms of insulin resistance in cystic fibrosis. Am J Physiol Endocrinol Metab. 2001;281(5):E1022-E1028.
4. Moran A, Hardin DS, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diab Res Clin Pract. 1999;45:61-73.
5. Schaedel C, de Monestrol I, Hjelte L, et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatc Pulmonol. 2004;33:483-491.
6. Fitz Simmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. 1993;122(1):1-9.
7. Berger M. Inflammatory mediators in cystic fibrosis lung disease. Allergy Asthma Proc. 2002;23:19-25.
8. Street ME, Ziveri MA, Spaggiari C, et al. Inflammation is a modulator of the IGF-IGFBP system inducing reduced bioactivity of IGFs in cystic fibrosis. Eur J Endocrinol. 2006;154:1-7.
9. Di Lorenzo F, Kubik Ł, Oblak A, et al. Activation of human toll-like receptor 4 (TLR4)·myeloid differentiation factor 2 (MD-2) by hy-poacylated lipopolysaccharide from a clinical isolate of Burkhold-eria cenocepacia. J Biol Chem. 2015;290:21305-21319.
10. Martel G, Rousseau S. TPL2 signalling: from Toll-like receptors-mediated ERK1/ERK2 activation to cystic fibrosis lung disease. Int J Biochem Cell Biol. 2014;52:146-151.
11. Smerieri A, Montanini L, Maiuri L, et al. FOXO1 content is reduced in cystic fibrosis, is related to CFTR loss of function, and increases with IGF-I treatment. Int J Mol Sci. 2014;15(10):18000-18022.
12. Mulrennan S, Baltic S, Aggarwal S, et al. The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes. Sci Rep. 2015;5:8931-8939.
13. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev. 2005; 5:331-342.
14. Chirico V, Lacquaniti A, Salpietro V, et al. High-mobility group box 1 (HMGB1) in childhood: from bench to bedside. Eur J Pediatr. 2014;173(9):1123-1136.
15. Entezari M, Weiss DJ, Sitapara R, et al. Inhibition of high-mobility group box 1 protein (HMGB1) enhances clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis. Mol Med. 2012;18:477-485.
16. Guzman-Ruiz R, Ortega F, Rodriguez A, et al. Alarmin high-mobility group B1 (HMGB1) is regulated in human adipocytes in insulin resistance and influences insulin secretion in β-cells. Int J Obesity. 2014;1-10.
17. Itoh T, Nitta T, Nishinakamura H, et al. HMGB1-mediated early loss of transplanted islets is prevented by anti-IL-6R antibody in mice. Pancreas. 2015;44:166-171.
18. Matsuoka N, Itoh T, Watarai H, et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest. 2010;120:735-743.
19. Arrigo T, Chirico V, Salpietro V, et al. High-mobility group protein B1: a new biomarker of metabolic syndrome in obese children. Eur J Endocrinol. 2013;168:631-638.
20. Chirico V, Lacquaniti A, Leonardi S, et al. Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: high-mobility group box 1 (HMGB1) between inflammation and infection. Clin Microbiol Infect. 2015;21:368e1-9.
21. Hagiwara S, Iwasaka H, Hasegawa A, Koga H, Noguchi T. Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit Care Med. 2008;36:2407-2413.
22. Street ME, Spaggiari C, Ziveri MA, et al. Insulin production and resistance in cystic fibrosis: effect of age, disease activity, and genotype. J Endocrinol Invest. 2012;35:246-253.
23. Marshall WA, Tanner J. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44(235):291-303(a).
24. Marshall WA, Tanner J. Variations in pattern of pubertal changes in boys. Arch Dis Child. 1969;45(239):13-23(b).
25. Cacciari E, Milani S, Balsamo A, et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest. 2006;29(7):581-593.
26. Quanjer PH. Standardized lung function testing. Report working party. Standardization of lung function test. European Community for Coal and Steel. Bull Eur Physiopathol Respir. 1983;19(suppl 5):1-82.
27. Borowitz D, Baker RD, Stallings V. Consensus Report on Nutrition for paediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;352:46-59.
28. Matsuda M, De Fronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-1470.
29. Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin; glucose; and FFA levels. Mol Gen Metab. 1998;63:134-141.
30. Uwaifo GI, Fallon EM, Chin J, et al. Indices of insulin action, disposal, and secretion derived from fasting samples and clamps in normal glucose-tolerant black and white children. Diabetes Care. 2002;25(11):2081-2087.
31. Gruenert DC, Willems M, Cassiman JJ, Frizzell RA. Established cell lines used in cystic fibrosis research. J Cyst Fibrosis. 2004;3(suppl 2):191-196.
32. Perez A, Issler AC, Cotton CU, et al. CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol. 2007;292:383-395.
33. Muanprasat C, Sonawane ND, Salinas D, et al. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol. 2004;124:125-137.
34. Yan XX, Lu L, Peng WH, et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis. 2009;205:544-548.
35. Hang Wang HQ, Huacong D. Plama HMGB-1 levels in subjects with obesity and type 2 diabetes: a cross-sectional study in China. PLoS One. 2015;28:1-10.
36. Garnett JP, Gray MA, Tarran R, et al. Elevated paracellular glucose flux across cystic fibrosis airway epithelial monolayers is an important factor for Pseudomonas aeruginosa growth. PLoS One. 2013; 8:e76283.1-8.
37. Brannan AL, Gyi KM, Wood DM, et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fi-brosis. J Cyst Fibrosis. 2007;6:101-109.
38. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32:1626-1631.
39. Mozzillo E, Franzese A, Valerio G, et al. One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes. 2009;10:162-167.
40. Bizzarri C, Lucidi V, Ciampalini P, Bella S, Russo B, Cappa M. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J Endocrinol Invest. 2006;29:RC1-RC4.
41. Dandona P, Ghanim H, Green K, et al. Insulin infusion suppresses while glucose infusion induces Toll-like receptors and high-mobility group-B1 protein expression in mononuclear cells of type 1 diabetes patients. Am J Physiol Endocrinol Metab. 2013;304:E810-E818.